Phase 1 Myasthenia Gravis Trial, Recruiting (NCT06626919)

Phase 1 Myasthenia Gravis Trial, Recruiting NCT06626919 Sponsor: Arcellx, Inc. Condition: Myasthenia Gravis

Printed from Voxsanity (voxsanity.com.au) — NCT06626919 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myasthenia Gravis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be 18 years of age or older
You must have a moderate to severe form of Myasthenia Gravis (MG), classified at a specific level of severity (Grades 2–4A on a medical scale used to measure MG — confirm with trial site)
Your MG must currently be active and you must be receiving ongoing treatment for it
Your MG symptoms must score at least 6 on one symptom scale (MG-ADL) and above 10 on another (QMG) — these measure how much MG affects your daily life and muscle strength (confirm with trial site)
Your blood tests must show that certain MG-related antibodies are above the normal reference range

Who may not be able to join:

You are currently pregnant or breastfeeding
You have recently been treated with certain immune-suppressing or related medications (such as azathioprine, methotrexate, or similar drugs) within a specific period before certain procedures in the trial (confirm exact timeframes with trial site)
You have previously received any gene therapy, CAR-T cell therapy, or a type of treatment called a T cell engager
You have had your thymus gland removed within the last 6 months before screening
You have a serious long-term illness that is not well controlled at the time of joining the study, based on the doctor's assessment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 240-327-0379

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06626919

Sponsor: Arcellx, Inc.

Phase: Phase 1

Status: Recruiting

Condition: Myasthenia Gravis

Trial contact: 240-327-0379

More information: https://clinicaltrials.gov/study/NCT06626919

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be 18 years of age or older
You must have a moderate to severe form of Myasthenia Gravis (MG), classified at a specific level of severity (Grades 2–4A on a medical scale used to measure MG — confirm with trial site)
Your MG must currently be active and you must be receiving ongoing treatment for it
Your MG symptoms must score at least 6 on one symptom scale (MG-ADL) and above 10 on another (QMG) — these measure how much MG affects your daily life and muscle strength (confirm with trial site)
Your blood tests must show that certain MG-related antibodies are above the normal reference range

Who may not be able to join:

You are currently pregnant or breastfeeding
You have recently been treated with certain immune-suppressing or related medications (such as azathioprine, methotrexate, or similar drugs) within a specific period before certain procedures in the trial (confirm exact timeframes with trial site)
You have previously received any gene therapy, CAR-T cell therapy, or a type of treatment called a T cell engager
You have had your thymus gland removed within the last 6 months before screening
You have a serious long-term illness that is not well controlled at the time of joining the study, based on the doctor's assessment

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Arcellx, Inc.

Registry

ClinicalTrials.gov

Start date

30 April 2025

Est. completion

1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assess safety profile, including any DLT and MTD (if applicable); Selection of RP2D

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov